Pakutanga se208-8-24, Cara Aripi 2022Q1. Cara naVifor vakasaina chibvumirano che Licence yeKorsuva ™ muUnited States uye vakabvuma kutengesa Korsuva ™ kune Frevenius kurapwa. Pakati pavo, Cara naVifor imwe neimwe ine 60% uye 40% purofiti yekugovera mari yekuchengetedza kunze kweFrosenius kurapwa; Imwe neimwe ine 50% purofiti yekugovera mumari yekutengesa kubva kuFlsenius yekurapa.
CKD-yakabatana PRURITUS (CKD-AP) ndeye generay pruritus iyo inoitika neyakakwira frequency uye kuwedzera muCKD varwere vari kugadzirwa nedombo. Pruritus inoitika munenge muna 60% -70% yevarwere vari kugashira dialysis, iyo 30% -40% yakanyanya kukanganisa hupenyu (semuenzaniso, hurombo hwekurara) uye hwakabatana nekuora mwoyo. Iko hakuna kurapwa kunobudirira kweCKD-kwakanangana naPruritus zvisati zvaitika, uye kutenderwa kwe diflikwafalin kunobatsira kugadzirisa kudiwa kwekurapa kwechikuru. Kubvumidzwa uku kunovakirwa pamiedzo yekiriniki yeIII INII MUNYAYA YEMADZIMAI YEMADZIMAI -
Nguva pfupi yapfuura, nhau dzakanaka dzakabva kuchidzidzo checintikefalin muJapan: 2022-18, Cara yakazivisa kuti jekiseni jekiseni rinoshandiswa muJapan kurapwa kwePruritus muHodiallys vasiri varwere. Phase III Makiriniki miedzo miedzo yekutanga yakasangana. 178 Varwere vakagamuchira mavhiki matanhatu eDikefalin kana Placebo uye vakatora chikamu mune 52-vhiki yakavhurika yekuwedzera kudzidza. Iyo yekutanga endpoint (shanduko mune pruritus nhamba yekuyera chiyero (shanduko muITCH chiratidzo pachiyero) zvakavandudzwa muboka rezvipenga zvichienzaniswa neboka reSpencebo uye vakanyudzwa.
Diflikwalin iboka reOpioid Peptides. Kubva pane izvi, Peptide Researn Institute yakadzidza mabhuku paOpioid Peptides, uye kupfupisa matambudziko uye marongero eOpioid Peptides mukusimudzira zvinodhaka, pamwe nemamiriro ezvinhu epazvino zvino zvinodhaka.
Post Nguva: Kukadzi-17-2022